These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 1375948

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG, MacInnes H, Bennett D, Weinstock H, Heneine W.
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG, Anderson KS.
    Biochemistry; 1997 Nov 18; 36(46):14064-70. PubMed ID: 9369478
    [Abstract] [Full Text] [Related]

  • 7. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA, Kemp SD.
    Science; 1989 Dec 01; 246(4934):1155-8. PubMed ID: 2479983
    [Abstract] [Full Text] [Related]

  • 8. Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.
    Mohri H, Singh MK, Ching WT, Ho DD.
    Proc Natl Acad Sci U S A; 1993 Jan 01; 90(1):25-9. PubMed ID: 7678340
    [Abstract] [Full Text] [Related]

  • 9. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
    Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R, Deacon NJ.
    J Med Virol; 1995 Jul 01; 46(3):238-43. PubMed ID: 7561796
    [Abstract] [Full Text] [Related]

  • 10. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 11. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
    Kellam P, Boucher CA, Larder BA.
    Proc Natl Acad Sci U S A; 1992 Mar 01; 89(5):1934-8. PubMed ID: 1371886
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility of HIV-1 isolates to zidovudine: correlation between widely applicable culture test and PCR analysis.
    Jung M, Agut H, Candotti D, Ingrand D, Katlama C, Huraux JM.
    J Acquir Immune Defic Syndr (1988); 1992 Mar 01; 5(4):359-64. PubMed ID: 1372352
    [Abstract] [Full Text] [Related]

  • 13. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Dis Markers; 1990 Mar 01; 8(3):163-4. PubMed ID: 1703061
    [No Abstract] [Full Text] [Related]

  • 14. Implication of the tRNA initiation step for human immunodeficiency virus type 1 reverse transcriptase in the mechanism of 3'-azido-3'-deoxythymidine (AZT) resistance.
    Vaccaro JA, Anderson KS.
    Biochemistry; 1998 Oct 06; 37(40):14189-94. PubMed ID: 9760256
    [Abstract] [Full Text] [Related]

  • 15. Interactions of the HIV-1 reverse transcriptase 'AZT-resistant' mutant with substrates and AZT-TP.
    Pokholok DK, Gudima SO, Yesipov DS, Dobrynin VN, Rechinsky VO, Kochetkov SN.
    FEBS Lett; 1993 Jul 05; 325(3):237-41. PubMed ID: 7686510
    [Abstract] [Full Text] [Related]

  • 16. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 17. Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera.
    Albert J, Wahlberg J, Lundeberg J, Cox S, Sandström E, Wahren B, Uhlén M.
    J Virol; 1992 Sep 30; 66(9):5627-30. PubMed ID: 1380098
    [Abstract] [Full Text] [Related]

  • 18. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
    Larder BA, Kemp SD, Harrigan PR.
    Science; 1995 Aug 04; 269(5224):696-9. PubMed ID: 7542804
    [Abstract] [Full Text] [Related]

  • 19. Characterization of reverse transcriptase activity and susceptibility to other nucleosides of AZT-resistant variants of HIV-1. Results from the Canadian AZT Multicentre Study.
    Wainberg MA, Tremblay M, Rooke R, Blain N, Soudeyns H, Parniak MA, Yao XJ, Li XG, Fanning M, Montaner JS.
    Ann N Y Acad Sci; 1990 Aug 04; 616():346-55. PubMed ID: 1706573
    [No Abstract] [Full Text] [Related]

  • 20. Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro.
    Muckenthaler M, Gunkel N, Levantis P, Broadhurst K, Goh B, Colvin B, Forster G, Jackson GG, Oxford JS.
    J Med Virol; 1992 Feb 04; 36(2):79-83. PubMed ID: 1374791
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.